Prioritizing drug targets in Clostridium botulinum with a computational systems biology approach

Syed Aun Muhammad1, Safia Ahmed2, Amjad Ali3

  • 1Department of Microbiology, Quaid-I-Azam University Islamabad, Pakistan; Indiana Center for Systems Biology and Personalized Medicine, Indiana University-Purdue University, Indianapolis, IN, USA.

Genomics
|May 20, 2014
PubMed

Insights

This study developed a computational framework to identify new antibacterial drug targets for Clostridium botulinum (Clb), addressing drug resistance and limited treatment options for botulism.

Area of Science:

  • Computational Biology
  • Microbiology
  • Drug Discovery

Background:

  • Clostridium botulinum (Clb) causes fatal flaccid paralysis, with drug-resistant strains and limited antitoxin treatments posing significant challenges.
  • Existing treatments are insufficient, highlighting the need for novel antibacterial strategies targeting Clb.

Purpose of the Study:

  • To develop and apply a systems-level computational framework for identifying and prioritizing novel antibacterial drug targets in Clostridium botulinum.
  • To identify potential drug targets that kill bacteria while minimizing host damage and side effects.

Main Methods:

  • Systematic analysis of Clostridium botulinum genome (2628 genes) to categorize essential, non-essential, and virulence genes.
  • Comparative genomics, including COGs and BLAST analysis, against human proteins and other bacteria to identify conserved and unique targets.
  • Phylogenetic analysis with human microbiota to filter targets affecting the gut flora.

Main Results:

  • Identified 39% of essential proteins interacting with virulence proteins as potential intervention points.
  • Filtered 47% of Clostridium botulinum proteins related to Homo sapiens to minimize off-target effects.
  • Reduced candidate drug targets to 131 proteins, with 68% located in the cytoplasm, including 6% virulent proteins.

Conclusions:

  • The developed computational framework effectively identifies and prioritizes Clostridium botulinum drug targets.
  • This strategy offers a generalizable approach for discovering antibacterial drug targets in other infectious diseases.